SR One co-led a round that included Celgene and Alexandria Venture Investments, as Gotham Therapeutics came out of stealth.
US-based biotechnology startup Gotham Therapeutics emerged from stealth yesterday with $54m in a series A round co-led by SR One, the strategic investment arm of pharmaceutical firm GlaxoSmithKline.
The round was co-led by investment firm Versant Ventures and venture capital firm Forbion, and included pharmaceutical company Celgene and Alexandria Venture Investments, the VC arm of life sciences real estate investment trust Alexandria Real Estate Equities.
Gotham is working on drugs intended to work by modifying the messenger RNA (mRNA) that…
